EUVIMEDEUVIMED entdecken
Metaanalyse

MRAs and Race in Heart Failure: An Individual Participant Data Meta-Analysis of Randomized Trials

MRA und Race bei Herzinsuffizienz: individuelle Patient:innendaten-Metaanalyse randomisierter Studien

Jawad H Butt iD, Pardeep S Jhund iD, Alasdair D Henderson iD, Atefeh Talebi iD, Orly Vardeny iD, Brian L Claggett iD, Muthiah Vaduganathan iD, Akshay S Desai iD, Marc A Pfeffer iD, Carolyn S P Lam iD, Michele Senni iD, Sanjiv J Shah iD und 9 weitere

Circulation: Heart Failure · 07.08.2026

DOI: 10.1161/circheartfailure.125.014355 ↗

Auf einen Blick

In 4 placebokontrollierten Studien war die Wirkung von MRAs bei Black und non-Black Patient:innen mit Herzinsuffizienz ähnlich. Für den primären Endpunkt zeigte sich keine statistisch signifikante Heterogenität.

Fragestellung

Unterscheidet sich die Wirksamkeit und Sicherheit von MRAs gegenüber Placebo bei Herzinsuffizienz je nach self-reported race (Black vs. non-Black)?

Methode

Post-hoc individuelle Patient:innendaten-Metaanalyse von 4 placebokontrollierten Studien bei Herzinsuffizienz mit reduzierter oder mildly reduced/preserved Ejection Fraction.

Ergebnisse

Primärer Endpunkt: HR 0.87 (95 %-KI 0.66–1.15) bei Black und 0.77 (95 %-KI 0.72–0.82) bei non-Black; P interaction =0.34. Adverse events wurden durch race nicht verändert.

Schlussfolgerung der Autor:innen

Es gab keinen statistisch signifikanten Hinweis auf Unterschiede in den absoluten oder relativen Effekten von MRAs zwischen Black und non-Black Patient:innen mit Herzinsuffizienz.

Kernaussagen

  • Primärer Endpunkt: HR 0.87 bei Black vs. 0.77 bei non-Black
  • Kein signifikanter Interaktionseffekt zwischen race und Behandlung
  • Nebenwirkungen von MRAs waren nicht durch race modifiziert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Circulation: Heart Failure, online erschienen am 07.08.2026. Verfasst von Jawad H Butt und 20 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.H.B., P.S.J., A.D.H., A.T., J.J.V.M.). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There are concerns that renin-angiotensin system inhibitors are less effective in Black patients than non-Black patients with heart failure (HF). We examined the efficacy and safety of mineralocorticoid-receptor antagonists (MRAs), compared with placebo, in patients with HF with reduced ejection fraction or HF with mildly reduced/preserved ejection fraction, according to self-reported race (Black or non-Black). METHODS: This was a post hoc individual participant data meta-analysis of the 4 large placebo-controlled trials comparing MRAs to placebo in patients with HF with reduced ejection fraction (RALES [Randomized Aldactone Evaluation Study], EMPHASIS-HF [Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure]) and HF with mildly reduced/preserved ejection fraction (TOPCAT [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist], FINEARTS-HF [Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure]). The primary outcome was a composite of cardiovascular death or first HF hospitalization. RESULTS: Of the 13 846 patients randomized in the 4 trials, 577 (4.2%) identified as Black. Despite being younger (64 versus 70 years), rates of HF hospitalizations and death were higher in Black than non-Black patients. The hazard ratio for MRA versus placebo for the primary composite outcome was 0.87 (95% CI, 0.66–1.15) in Black patients and 0.77 (95% CI, 0.72–0.82) in non-Black patients ( P interaction =0.34), with 3.9 and 2.7 fewer events per 100 person-years of treatment, respectively. For first HF hospitalization, the hazard ratios were 0.86 (95% CI, 0.63–1.17) and 0.73 (95% CI, 0.68–0.80) for Black and non-Black patients, respectively ( P interaction =0.36). The corresponding hazard ratios for cardiovascular death were 0.75 (95% CI, 0.48–1.17) and 0.81 (95% CI, 0.74–0.90), respectively ( P interaction =0.80). Adverse events with MRAs, compared with placebo, were not modified by race. The effects of MRAs in patients with HF with reduced ejection fraction and HF with preserved ejection fraction, individually, were not modified by race. CONCLUSIONS: There was no statistically significant evidence of heterogeneity in the absolute or relative effects of MRAs on clinical outcomes between Black and non-Black patients with HF, regardless of HF phenotype.

Schlagwörter

Stichwörter der Autor:innen

angiotensin-converting enzymeheart failurehospitalizationmineralocorticoid-receptor antagonistsphenotype

Autor:innen und Institutionen

  • British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.H.B., P.S.J., A.D.H., A.T., J.J.V.M.).
  • Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Denmark (J.H.B.).
  • Department of Cardiology, Copenhagen University Hospital, Herlev-Gentofte, Denmark (J.H.B.).
  • Department of Cardiology, Zealand University Hospital, Roskilde, Denmark (J.H.B.).
  • The Minneapolis Veterans Affairs Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis (O.V.).
  • Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.L.C., M.V., A.S.D., M.A.P., S.D.S.).

ORCID-Profile: Jawad H Butt, Pardeep S Jhund, Alasdair D Henderson, Atefeh Talebi, Orly Vardeny, Brian L Claggett, Muthiah Vaduganathan, Akshay S Desai, Marc A Pfeffer, Carolyn S P Lam, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Dirk J van Veldhuisen, Subodh Verma, Faiez Zannad, Bertram Pitt, Scott D Solomon, John J V McMurray

Zitieren

APA

Butt, J. H., Jhund, P. S., Henderson, A. D., Talebi, A., Vardeny, O., Claggett, B. L., Vaduganathan, M., Desai, A. S., Pfeffer, M. A., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., van Veldhuisen, D. J., Verma, S., Lewis, E. F., Zannad, F., Pitt, B., Solomon, S. D., …, & McMurray, J. J. V. (2026). MRAs and Race in Heart Failure: An Individual Participant Data Meta-Analysis of Randomized Trials. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.125.014355

Vancouver

Butt JH, Jhund PS, Henderson AD, Talebi A, Vardeny O, Claggett BL, et al. MRAs and Race in Heart Failure: An Individual Participant Data Meta-Analysis of Randomized Trials. Circulation: Heart Failure. 2026. doi:10.1161/circheartfailure.125.014355

BibTeX
@article{Butt2026,
  author = {Butt, Jawad H and Jhund, Pardeep S and Henderson, Alasdair D and Talebi, Atefeh and Vardeny, Orly and Claggett, Brian L and Vaduganathan, Muthiah and Desai, Akshay S and Pfeffer, Marc A and Lam, Carolyn S P and Senni, Michele and Shah, Sanjiv J and Voors, Adriaan A and van Veldhuisen, Dirk J and Verma, Subodh and Lewis, Eldrin F and Zannad, Faiez and Pitt, Bertram and Solomon, Scott D and McMurray, John J V and McMurray, John J V},
  title = {MRAs and Race in Heart Failure: An Individual Participant Data Meta-Analysis of Randomized Trials},
  journal = {Circulation: Heart Failure},
  year = {2026},
  doi = {10.1161/circheartfailure.125.014355}
}
Kostenlos starten →